Jazz Pharmaceuticals (JAZZ) Misses Q2 EPS by 47c; raises guidance
Tweet
Share
E-mail
Get Alerts JAZZ Hot Sheet
Price: $246.81 -0.31%
Revenue Growth %: +7.1%
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +7.1%
Financial Fact:
Intangible asset amortization: 26.45M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $5.71, $0.47 worse than the analyst estimate of $6.18. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1.11 billion.
GUIDANCE:
Jazz Pharmaceuticals sees FY2026 revenue of $4.600-4.750 billion, versus the consensus of $4.512 billion.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
- ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
